OTCMKTS:ABMC

American Bio Medica Competitors

$0.09
0.00 (0.00 %)
(As of 04/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.09
Now: $0.09
$0.10
50-Day Range
$0.09
MA: $0.13
$0.19
52-Week Range
$0.07
Now: $0.09
$1.26
Volume403,163 shs
Average Volume322,335 shs
Market Capitalization$3.60 million
P/E RatioN/A
Dividend YieldN/A
Beta-1.45

Competitors

American Bio Medica (OTCMKTS:ABMC) Vs. NVLNF, NTEC, NRIFF, MCUJF, CPMD, and CPMD

Should you be buying ABMC stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to American Bio Medica, including Novelion Therapeutics (NVLNF), Intec Pharma (NTEC), Nuvo Pharmaceuticals (NRIFF), Medicure (MCUJF), CannaPharmaRX (CPMD), and CannaPharmaRX (CPMD).

Novelion Therapeutics (OTCMKTS:NVLNF) and American Bio Medica (OTCMKTS:ABMC) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings and valuation.

Valuation and Earnings

This table compares Novelion Therapeutics and American Bio Medica's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Novelion Therapeutics$130.43 million0.11$-108,330,000.00N/AN/A
American Bio Medica$3.65 million0.99$-680,000.00N/AN/A

American Bio Medica has lower revenue, but higher earnings than Novelion Therapeutics.

Profitability

This table compares Novelion Therapeutics and American Bio Medica's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Novelion TherapeuticsN/AN/AN/A
American Bio Medica-18.99%N/A-35.34%

Risk and Volatility

Novelion Therapeutics has a beta of 2.15, indicating that its stock price is 115% more volatile than the S&P 500. Comparatively, American Bio Medica has a beta of -1.45, indicating that its stock price is 245% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations and price targets for Novelion Therapeutics and American Bio Medica, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Novelion Therapeutics0000N/A
American Bio Medica0000N/A

Insider & Institutional Ownership

48.6% of Novelion Therapeutics shares are held by institutional investors. 3.6% of Novelion Therapeutics shares are held by company insiders. Comparatively, 13.0% of American Bio Medica shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Novelion Therapeutics beats American Bio Medica on 5 of the 8 factors compared between the two stocks.

Intec Pharma (NASDAQ:NTEC) and American Bio Medica (OTCMKTS:ABMC) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, dividends and risk.

Profitability

This table compares Intec Pharma and American Bio Medica's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Intec PharmaN/A-93.54%-63.98%
American Bio Medica-18.99%N/A-35.34%

Analyst Recommendations

This is a summary of recent ratings and price targets for Intec Pharma and American Bio Medica, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Intec Pharma03102.25
American Bio Medica0000N/A

Intec Pharma currently has a consensus price target of $13.00, indicating a potential upside of 239.43%. Given Intec Pharma's higher possible upside, research analysts clearly believe Intec Pharma is more favorable than American Bio Medica.

Earnings & Valuation

This table compares Intec Pharma and American Bio Medica's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Intec PharmaN/AN/A$-47,600,000.00($21.80)-0.18
American Bio Medica$3.65 million0.99$-680,000.00N/AN/A

American Bio Medica has higher revenue and earnings than Intec Pharma.

Summary

American Bio Medica beats Intec Pharma on 4 of the 7 factors compared between the two stocks.

Nuvo Pharmaceuticals (OTCMKTS:NRIFF) and American Bio Medica (OTCMKTS:ABMC) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends and earnings.

Profitability

This table compares Nuvo Pharmaceuticals and American Bio Medica's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Nuvo Pharmaceuticals-2.81%8.02%1.11%
American Bio Medica-18.99%N/A-35.34%

Volatility & Risk

Nuvo Pharmaceuticals has a beta of 1.57, meaning that its share price is 57% more volatile than the S&P 500. Comparatively, American Bio Medica has a beta of -1.45, meaning that its share price is 245% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Nuvo Pharmaceuticals and American Bio Medica, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Nuvo Pharmaceuticals0000N/A
American Bio Medica0000N/A

Earnings and Valuation

This table compares Nuvo Pharmaceuticals and American Bio Medica's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nuvo Pharmaceuticals$52.41 million0.26$2.53 millionN/AN/A
American Bio Medica$3.65 million0.99$-680,000.00N/AN/A

Nuvo Pharmaceuticals has higher revenue and earnings than American Bio Medica.

Summary

Nuvo Pharmaceuticals beats American Bio Medica on 6 of the 7 factors compared between the two stocks.

Medicure (OTCMKTS:MCUJF) and American Bio Medica (OTCMKTS:ABMC) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, valuation and dividends.

Earnings and Valuation

This table compares Medicure and American Bio Medica's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Medicure$15.20 million0.90$-14,910,000.00N/AN/A
American Bio Medica$3.65 million0.99$-680,000.00N/AN/A

American Bio Medica has lower revenue, but higher earnings than Medicure.

Analyst Ratings

This is a summary of current recommendations and price targets for Medicure and American Bio Medica, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Medicure0000N/A
American Bio Medica0000N/A

Risk & Volatility

Medicure has a beta of 0.68, suggesting that its stock price is 32% less volatile than the S&P 500. Comparatively, American Bio Medica has a beta of -1.45, suggesting that its stock price is 245% less volatile than the S&P 500.

Profitability

This table compares Medicure and American Bio Medica's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Medicure-179.92%-63.27%-41.85%
American Bio Medica-18.99%N/A-35.34%

Summary

American Bio Medica beats Medicure on 5 of the 7 factors compared between the two stocks.

American Bio Medica (OTCMKTS:ABMC) and CannaPharmaRX (OTCMKTS:CPMD) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, dividends, profitability, valuation and earnings.

Analyst Ratings

This is a breakdown of recent ratings and price targets for American Bio Medica and CannaPharmaRX, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
American Bio Medica0000N/A
CannaPharmaRX0000N/A

Risk and Volatility

American Bio Medica has a beta of -1.45, suggesting that its stock price is 245% less volatile than the S&P 500. Comparatively, CannaPharmaRX has a beta of 1.85, suggesting that its stock price is 85% more volatile than the S&P 500.

Earnings and Valuation

This table compares American Bio Medica and CannaPharmaRX's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
American Bio Medica$3.65 million0.99$-680,000.00N/AN/A
CannaPharmaRXN/AN/A$-20,450,000.00N/AN/A

American Bio Medica has higher revenue and earnings than CannaPharmaRX.

Profitability

This table compares American Bio Medica and CannaPharmaRX's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
American Bio Medica-18.99%N/A-35.34%
CannaPharmaRXN/A-726.81%-96.06%

Summary

American Bio Medica beats CannaPharmaRX on 4 of the 6 factors compared between the two stocks.

American Bio Medica (OTCMKTS:ABMC) and CannaPharmaRX (OTCMKTS:CPMD) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, dividends, earnings and risk.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for American Bio Medica and CannaPharmaRX, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
American Bio Medica0000N/A
CannaPharmaRX0000N/A

Valuation and Earnings

This table compares American Bio Medica and CannaPharmaRX's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
American Bio Medica$3.65 million0.99$-680,000.00N/AN/A
CannaPharmaRXN/AN/A$-20,450,000.00N/AN/A

American Bio Medica has higher revenue and earnings than CannaPharmaRX.

Profitability

This table compares American Bio Medica and CannaPharmaRX's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
American Bio Medica-18.99%N/A-35.34%
CannaPharmaRXN/A-726.81%-96.06%

Risk & Volatility

American Bio Medica has a beta of -1.45, suggesting that its share price is 245% less volatile than the S&P 500. Comparatively, CannaPharmaRX has a beta of 1.85, suggesting that its share price is 85% more volatile than the S&P 500.

Summary

American Bio Medica beats CannaPharmaRX on 4 of the 6 factors compared between the two stocks.


American Bio Medica Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
NVLNF
Novelion Therapeutics
0.6$0.70flat$13.77 million$130.43 million0.00Gap Down
Intec Pharma logo
NTEC
Intec Pharma
1.4$3.83flat$13.76 millionN/A-0.54
NRIFF
Nuvo Pharmaceuticals
0.7$1.20flat$13.68 million$52.41 million30.00Gap Down
Medicure logo
MCUJF
Medicure
0.6$1.33flat$13.63 million$15.20 million-1.06Gap Down
CannaPharmaRX logo
CPMD
CannaPharmaRX
0.3$0.24flat$12.04 millionN/A-0.47Decrease in Short Interest
News Coverage
Gap Up
CannaPharmaRX logo
CPMD
CannaPharmaRX
0.3$0.24flat$12.04 millionN/A-0.47Decrease in Short Interest
News Coverage
Gap Up
Acerus Pharmaceuticals logo
TRLPF
Acerus Pharmaceuticals
0.5$0.05flat$12.03 million$7.38 million0.00High Trading Volume
Gap Down
iCo Therapeutics logo
ICOTF
iCo Therapeutics
0.5$0.08flat$11.99 millionN/A-3.90Decrease in Short Interest
Tower One Wireless logo
TOWTF
Tower One Wireless
0.0$0.12flat$11.59 million$4.08 million-1.38Increase in Short Interest
News Coverage
Gap Up
Teligent logo
TLGT
Teligent
1.2$0.53flat$11.46 million$65.90 million-0.06News Coverage
Gap Up
BetterLife Pharma logo
BETRF
BetterLife Pharma
0.0$0.66flat$11.37 millionN/A-0.88Gap Down
Peak Pharmaceuticals logo
PKPH
Peak Pharmaceuticals
0.7$0.13flat$10.33 millionN/A0.00Gap Up
Williston logo
WHCA
Williston
0.0$0.70flat$9.51 millionN/A0.00
Acura Pharmaceuticals logo
ACUR
Acura Pharmaceuticals
0.6$0.42flat$9.28 million$2.66 million-14.00
GlobeImmune logo
GBIM
GlobeImmune
0.5$1.55flat$8.91 millionN/A0.00
ULUR
ULURU
0.3$0.28flat$8.17 millionN/A0.00
Nexien BioPharma logo
NXEN
Nexien BioPharma
0.0$0.13flat$7.33 millionN/A0.00Gap Up
Parnell Pharmaceuticals logo
PARNF
Parnell Pharmaceuticals
0.5$0.36flat$7.20 millionN/A0.00
Pivotal Therapeutics logo
PVTTF
Pivotal Therapeutics
0.6$0.08flat$7.15 millionN/A0.00
KAYS
Kaya
0.7$0.44flat$6.35 million$1.01 million0.00Gap Up
Wellness Center USA logo
WCUI
Wellness Center USA
0.5$0.05flat$5.71 million$30,000.000.00High Trading Volume
Gap Up
Intellipharmaceutics International logo
IPCIF
Intellipharmaceutics International
0.6$0.20flat$4.74 million$3.48 million-1.67
BCTXF
BriaCell Therapeutics
0.0N/AN/A$4.59 millionN/A-0.01
FutureWorld logo
FWDG
FutureWorld
0.5$0.00flat$4.56 millionN/A0.00Gap Down
International Stem Cell logo
ISCO
International Stem Cell
0.8$0.60flat$4.52 million$9.47 million0.00High Trading Volume
Gap Up
AMBS
Amarantus BioScience
0.0$0.01flat$3.87 millionN/A0.00Increase in Short Interest
Gap Down
AKRXQ
Akorn
0.1$0.03flat$3.60 million$682.43 million-0.01
VG Life Sciences logo
VGLS
VG Life Sciences
0.0$0.01flat$3.50 millionN/A0.00Gap Up
INNVD
Innovus Pharmaceuticals
0.6N/AN/A$2.90 million$23.99 million-0.72Gap Down
Immune Pharmaceuticals logo
IMNPQ
Immune Pharmaceuticals
0.0$0.14flat$2.88 millionN/A0.00Gap Down
RSPI
RespireRx Pharmaceuticals
0.5$0.04flat$2.87 millionN/A-0.09Gap Down
Boston Therapeutics logo
BTHE
Boston Therapeutics
0.5$0.02flat$2.20 million$20,000.00-0.99Gap Up
IMUCD
ImmunoCellular Therapeutics
0.0$0.51flat$2.14 millionN/A0.00Gap Up
VVUSQ
VIVUS
0.6$0.12flat$2.10 million$69.76 million-0.04
NSPX
Inspyr Therapeutics
0.5$0.01flat$1.97 millionN/A0.00Gap Up
Capstone Therapeutics logo
CAPS
Capstone Therapeutics
0.8$36.01flat$1.95 million$2 million0.00
Earth Science Tech logo
ETST
Earth Science Tech
0.5$0.04flat$1.83 million$530,000.000.00
WWHC
W World
0.8$6.09flat$1.80 millionN/A0.00Increase in Short Interest
ImmunoCellular Therapeutics logo
IMUC
ImmunoCellular Therapeutics
0.0$0.48flat$1.70 millionN/A0.00Gap Up
Cardax logo
CDXI
Cardax
0.0$2.00flat$1.59 million$710,000.000.00News Coverage
MLNTQ
Melinta Therapeutics
0.2$0.11flat$1.51 million$96.43 million0.00
Achaogen logo
AKAOQ
Achaogen
0.6$0.03flat$1.30 million$8.73 million0.00Gap Up
Propanc Biopharma logo
PPCB
Propanc Biopharma
0.7$0.24flat$1.27 millionN/A0.00Decrease in Short Interest
Gap Up
AOXG
Aoxing Pharmaceutical
0.5$0.02flat$1.17 millionN/A0.00
Cotinga Pharmaceuticals logo
COTQF
Cotinga Pharmaceuticals
0.4$0.05flat$1.12 millionN/A-0.57Upcoming Earnings
High Trading Volume
Gap Up
AOLS
Aeolus Pharmaceuticals
0.8$0.01flat$1.07 millionN/A0.00Increase in Short Interest
Gap Down
TetraLogic Pharmaceuticals logo
TLOG
TetraLogic Pharmaceuticals
0.5$0.04flat$978,000.00N/A0.00Gap Up
Anthera Pharmaceuticals logo
ANTH
Anthera Pharmaceuticals
0.5$0.07flat$970,000.00N/A0.00Increase in Short Interest
Gap Up
ATRX
Adhera Therapeutics
0.0$0.08flat$872,000.00$250,000.000.00
PXYN
Praxsyn
0.6$0.00flat$848,000.00N/A0.00Increase in Short Interest
News Coverage
This page was last updated on 4/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.